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Variceal bleeding is a life-threatening complication of portal hypertension. The
recommended treatment includes the early administration of a vasoactive drug.
Vapreotide is a somatostatin analogue with a different receptor affinity to
octreotide. It decreases portal pressure and blood flow of collateral circulation in
rats with cirrhosis. The pivotal study of early administration of vapreotide in
patients with cirrhosis and variceal bleeding has shown a significant improvement
in bleeding control and, in the subset of patients with significant bleeding, a
significant reduction in mortality. In addition, a meta-analysis of four randomized
studies has shown a significant improvement in bleeding control. Vapreotide
administrated via the intravenous route is simple to use, with practically no
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